1.82
-0.01 (-0.55%)
| Penutupan Terdahulu | 1.83 |
| Buka | 1.89 |
| Jumlah Dagangan | 4,541,616 |
| Purata Dagangan (3B) | 3,278,522 |
| Modal Pasaran | 116,688,208 |
| Harga / Jualan (P/S) | 10.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Feb 2026 |
| EPS Cair (TTM) | 4.09 |
| Nisbah Semasa (MRQ) | 0.720 |
| Aliran Tunai Operasi (OCF TTM) | -64.05 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.91 M |
| Pulangan Atas Aset (ROA TTM) | -122.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Outlook Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -2.00 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 38.31% |
| % Dimiliki oleh Institusi | 16.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lvw Advisors, Llc | 30 Sep 2025 | 48,235 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Ascendiant Capital, 449.45%) | Beli |
| Median | 1.00 (-45.06%) | |
| Rendah | 0.500 (HC Wainwright & Co., -72.53%) | Pegang |
| Purata | 3.83 (110.44%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 1.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 1.00 (-45.05%) | Pegang | 0.543 |
| HC Wainwright & Co. | 02 Jan 2026 | 0.500 (-72.53%) | Pegang | 0.660 |
| Ascendiant Capital | 22 Dec 2025 | 10.00 (449.45%) | Beli | 1.84 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2026 | Pengumuman | Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development |
| 31 Dec 2025 | Pengumuman | Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD |
| 26 Dec 2025 | Pengumuman | Outlook Therapeutics Announces New Employment Inducement Grants |
| 19 Dec 2025 | Pengumuman | Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 |
| 24 Nov 2025 | Pengumuman | Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Pengumuman | Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |